文献速递免疫规划传染病防控与疫情报告

马德里13价肺炎球菌结合疫苗对15岁以下儿童侵袭性肺炎球菌疾病的影响:HERACLES临床监测研究

Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study.
PubMed 文献 · Vaccine · 2019-03-19

基于西班牙马德里HERACLES临床监测研究(2007-2016)数据,评估13价肺炎球菌结合疫苗(PCV13)纳入免疫规划后对15岁以下儿童侵袭性肺炎球菌疾病(IPD)的人群影响。PCV13纳入免疫规划六年后(2010-2016),尽管地区免疫规划限制其可及性,IPD净获益发病率下降70.1%(IRR 0.3 [95% CI: 0.22-0.4];p ≤ 0.001),主要因PCV13血清型IPD显著减少91%(IRR 0.09 [95% CI: 0.05-0.16],p ≤ 0.001)。非PCV13血清型IPD发病率无显著变化。侵袭性强、耐药且最常见的19A血清型发病率从研究开始至结束大幅下降98%[IRR 0.03 (95% CI: 0.00-0.19),p ≤ 0.001],几乎完全消失。该减少导致头孢噻肟耐药分离株比例和脑膜炎病例发病率显著下降。临床影响评估显示所有临床类型的IPD数量均减少,证实PCV13有效性。PCR检测的PCV13预计影响强于培养方法,培养法可能遗漏超过20%的IPD病例,主要为脓胸。

要点

  • PCV13纳入免疫规划六年后,15岁以下儿童IPD净获益发病率下降70.1%。
  • PCV13血清型IPD减少91%,非PCV13血清型IPD无显著变化。
  • 19A血清型IPD下降98%几乎消失,头孢噻肟耐药和脑膜炎病例显著减少。

核心结论

  • PCV13纳入免疫规划六年后,尽管地区免疫规划限制其可及性,15岁以下儿童IPD净获益发病率下降70.1%,主要因PCV13血清型IPD减少91%。
  • 非PCV13血清型IPD发病率无显著变化,19A血清型IPD下降98%几乎消失,头孢噻肟耐药分离株比例和脑膜炎病例发病率显著下降。
  • PCR检测的PCV13预计影响强于培养方法,培养法可能遗漏超过20%的IPD病例,主要为脓胸。

研究设计与样本

  • 基于HERACLES临床监测研究(2007-2016)数据,描述西班牙马德里社区15岁以下儿童PCV13对IPD的人群影响。

主要发现

  • PCV13纳入免疫规划六年后(2010-2016),IPD净获益发病率下降70.1%(IRR 0.3 [95% CI: 0.22-0.4];p ≤ 0.001)。
  • PCV13血清型IPD减少91%(IRR 0.09 [95% CI: 0.05-0.16],p ≤ 0.001),非PCV13血清型IPD发病率无显著变化。
  • 19A血清型IPD从研究开始至结束下降98%[IRR 0.03 (95% CI: 0.00-0.19),p ≤ 0.001],几乎完全消失。
  • 头孢噻肟耐药分离株比例和脑膜炎病例发病率显著下降,所有临床类型的IPD数量均减少。
  • PCR检测的PCV13预计影响强于培养方法,培养法可能遗漏超过20%的IPD病例,主要为脓胸。

临床怎么用

  • 监测数据显示PCV13纳入免疫规划可大幅降低儿童IPD发病率,支持维持PCV13接种。
  • 应注意培养法可能低估IPD负担,PCR检测可提高检出率,尤其对脓胸病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide. Using the data from the HERACLES clinical surveillance study (2007-2016), we describe the population impact of the 13-valent pneumococcal conjugate vaccine (PVC13) on invasive pneumococcal disease (IPD) in children <15 years of age in the Community of Madrid, Spain. After six years of the inclusion of PCV13 in the vaccination calendar (2010-2016), and despite changes in the Regional Immunization Programme that limited its availability, the net benefit incidence rate (IR) of IPD fell by 70.1% (IRR 0.3 [95% CI: 0.22-0.4]; p ≤ 0.001), mainly due to a significant reduction (91%) in the PCV13 serotypes (IRR 0.09 [95% CI: 0.05-0.16], p ≤ 0.001). Furthermore, no significant changes were detected in the IR of IPD caused by non-PCV13 serotypes. The IRs of the aggressive, resistant and most prevalent serotype in the analysed population, the 19A serotype, dramatically decreased from the beginning to the end of the study (98%) [IRR 0.03 (95% CI: 0.00-0.19), p ≤ 0.001], to its almost total disappearance. Remarkably, this reduction led to a pronounced decline in the percentage of cefotaxime-resistant isolates and the incidence of meningitis cases. Assessment of the clinical impact revealed a reduction in the number of all clinical presentations of IPD, confirming the effectiveness of the PCV13. Finally, PCV13 detected by PCR is predicted to have a stronger impact than the one based on culture methods, which can overlook more than 20% of cases of IPD, mainly pleural empyemas.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Picazo JJ, Ruiz-Contreras J, Casado-Flores J, et al. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study. Vaccine. 2019. PMID: 30902478. doi:10.1016/j.vaccine.2019.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。